- Home
- DMAC vs GLDG Comparison
DMAC vs GLDG Comparison
Compare DMAC & GLDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- GLDG
- Stock Information
- Founded
- DMAC 2000
- GLDG 2009
- Country
- DMAC United States
- GLDG Canada
- Employees
- DMAC N/A
- GLDG N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- GLDG Precious Metals
- Sector
- DMAC Health Care
- GLDG Basic Materials
- Exchange
- DMAC Nasdaq
- GLDG Nasdaq
- Market Cap
- DMAC 321.5M
- GLDG 317.0M
- IPO Year
- DMAC N/A
- GLDG N/A
- Fundamental
- Price
- DMAC $5.95
- GLDG $1.31
- Analyst Decision
- DMAC Strong Buy
- GLDG Strong Buy
- Analyst Count
- DMAC 4
- GLDG 2
- Target Price
- DMAC $15.50
- GLDG $3.50
- AVG Volume (30 Days)
- DMAC 315.3K
- GLDG 1.9M
- Earning Date
- DMAC 11-12-2025
- GLDG 10-10-2025
- Dividend Yield
- DMAC N/A
- GLDG N/A
- EPS Growth
- DMAC N/A
- GLDG N/A
- EPS
- DMAC N/A
- GLDG N/A
- Revenue
- DMAC N/A
- GLDG N/A
- Revenue This Year
- DMAC N/A
- GLDG N/A
- Revenue Next Year
- DMAC N/A
- GLDG N/A
- P/E Ratio
- DMAC N/A
- GLDG N/A
- Revenue Growth
- DMAC N/A
- GLDG N/A
- 52 Week Low
- DMAC $3.19
- GLDG $0.71
- 52 Week High
- DMAC $7.49
- GLDG $1.80
- Technical
- Relative Strength Index (RSI)
- DMAC 42.03
- GLDG 46.78
- Support Level
- DMAC $5.26
- GLDG $1.22
- Resistance Level
- DMAC $6.47
- GLDG $1.45
- Average True Range (ATR)
- DMAC 0.41
- GLDG 0.08
- MACD
- DMAC -0.10
- GLDG -0.01
- Stochastic Oscillator
- DMAC 36.50
- GLDG 43.48
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About GLDG GoldMining Inc.
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; Crucero project, located in Peru; Sao Jorge, Batistao, located in Brazil; Yellowknife Gold Project, located in the Northwest Territories, Canada; and various other projects such as Cachoeira, Yarumalito, Whistler, Surubim, Montes Aureos and Trinta, Rea across different locations. The company has two operating segments, with U.S. GoldMining being one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.